Evolutionary conservation of drug action on lipoprotein metabolism-related targets

Journal of Lipid Research

Volumn 49, Issue 1, 2008, Pages 74-83

  Hihi, Abdelmadjid K ^a   Beauchamp, Marie Claude ^a   Branicky, Robyn ^a,b   Desjardins, Annick ^a   Casanova, Isabel ^a   Guimond, Marie Pierre ^a   Carroll, Melissa ^a   Ethier, Melanie ^a   Kianicka, Irenej ^a   McBride, Kevin ^a   Hekimi, Siegfried ^a,b  

^a Chronogen Inc   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Caenorhabditis elegans; clk 1; Drug discovery; Dyslipidemia; High density lipoprotein; Low density lipoprotein; Phenylthiourea; Reverse cholesterol transport

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CHGN 005; CHOLESTEROL; CIGLITAZONE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPOPROTEIN; MEVINOLIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; DRUG ACTIVITY; DRUG MECHANISM; DYSLIPIDEMIA; GENETIC CONSERVATION; HUMAN; HUMAN CELL; LIPOPROTEIN METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; CACO-2 CELLS; CAENORHABDITIS ELEGANS; CAENORHABDITIS ELEGANS PROTEINS; CELL LINE, TUMOR; CHOLESTEROL; DRUG EVALUATION, PRECLINICAL; EVOLUTION, MOLECULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; LIPOPROTEINS; MICE; MUTATION; SMALL MOLECULE LIBRARIES; TRIGLYCERIDES;

EID: 38049125637     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M700167-JLR200     Document Type: Article

References (60)

1. Kwok, T. C., N. Ricker, R. Fraser, A. W. Chan, A. Burns, E. F. Stanley, P. McCourt, S. R. Cutler, and P. J. Roy. 2006. A smallmolecule screen in C. elegans yields a new calcium channel antagonist. Nature. 441: 91-95.
2. Kaletta, T., and M. O. Hengartner. 2006. Finding function in novel targets: C. elegans as a model organism. Nat. Rev. Drug Discov. 5: 387-398.
3. Chitwood, D. J. 1999. Biochemistry and function of nematode steroids. Crit. Rev. Biochem. Mol. Biol. 34: 273-284.
4. Entchev, E. V., and T. V. Kurzchalia. 2005. Requirement of sterols in the life cycle of the nematode Caenorhabditis elegans. Semin. Cell Dev. Biol. 16: 175-182.
5. Hieb, W. F., and M. Rothstein. 1968. Sterol requirement for reproduction of a free-living nematode. Science. 160: 778-780.
6. Kurzchalia, T. V., and S. Ward. 2003. Why do worms need cholesterol? Nat. Cell Biol. 5: 684-688.
7. Kubagawa, H. M., J. L. Watts, C. Corrigan, J. W. Edmonds, E. Sztul, J. Browse, and M. A. Miller. 2006. Oocyte signals derived from polyunsaturated fatty acids control sperm recruitment in vivo. Nat. Cell Biol. 8: 1143-1148.
8. McKay, R. M., J. P. McKay, L. Avery, and J. M. Graff. 2003. C elegans: a model for exploring the genetics of fat storage. Dev. Cell. 4: 131-142.
9. Ashrafi, K., F. Y. Chang, J. L. Watts, A. G. Fraser, R. S. Kamath, J. Ahringer, and G. Ruvkun. 2003. Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature. 421: 268-272.
10. Sym, M., M. Basson, and C. Johnson. 2000. A model for Niemann-Pick type C disease in the nematode Caenorhabditis elegans. Curr. Biol. 10: 527-530.
11. Li, J., G. Brown, M. Ailion, S. Lee, and J. H. Thomas. 2004. NCR-1 and NCR-2, the C. elegans homologs of the human Niemann-Pick type C1 disease protein, function upstream of DAF-9 in the Dauer formation pathways. Development. 131: 5741-5752.
12. Miyadera, H., H. Amino, A. Hiraishi, H. Taka, K. Murayama, H. Miyoshi, K. Sakamoto, N. Ishii, S. Hekimi, and K. Kita. 2001. Altered quinone biosynthesis in the long-lived clk-1 mutants of Caenorhabditis elegans. J. Biol. Chem. 276: 7713-7716.
13. Branicky, R., Y. Shibata, J. Feng, and S. Hekimi. 2001. Phenotypic and suppressor analysis of defecation in clk-1 mutants reveals that reaction to changes in temperature is an active process in Caenorhabditis elegans. Genetics. 159: 997-1006.
14. Branicky, R., C. Benard, and S. Hekimi. 2000. clk-1, mitochondria, and physiological rates. Bioessays. 22: 48-56.
15. Wong, A., P. Boutis, and S. Hekimi. 1995. Mutations in the clk-1 gene of Caenorhabditis elegans affect developmental and behavioral timing. Genetics. 139: 1247-1259.
16. Thomas, J. H. 1990. Genetic analysis of defecation in Caenorhabditis elegans. Genetics. 124: 855-872.
17. Branicky, R., and S. Hekimi. 2006. What keeps C. elegans regular: the genetics of defecation. Trends Genet. 22: 571-579.
18. Shibata, Y., R. Branicky, I. O. Landaverde, and S. Hekimi. 2003. Redox regulation of germline and vulval development in Caenorhabditis elegans. Science. 302: 1779-1782.
19. Hussain, M. M., J. Shi, and P. Dreizen. 2003. Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J. Lipid Res. 44: 22-32.
20. Smolenaars, M. M., O. Madsen, K. W. Rodenburg, and D. J. Van der Horst. 2007. Molecular diversity and evolution of the large lipid transfer protein superfamily. J. Lipid Res. 48: 489-502.
21. Shelness, G. S., and A. S. Ledford. 2005. Evolution and mechanism of apolipoprotein B-containing lipoprotein assembly. Curr. Opin. Lipidol. 16: 325-332.
22. Terasaka, N., A. Hiroshima, T. Koieyama, N. Ubukata, Y. Morikawa, D. Nakai, and T. Inaba. 2003. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536: 6-11.
23. Lambe, K. G., and J. D. Tugwood. 1996. A human peroxisomeproliferator- activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur. J. Biochem. 239: 1-7.
24. Rubins, H. B., S. J. Robins, D. Collins, C. L. Fye, J. W. Anderson, M. B. Elam, F. H. Faas, E. Linares, E. J. Schaefer, G. Schectman, et al. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341: 410-418.
25. Coppola, G. M., R. E. Damon, J. B. Eskesen, D. S. France, and J. R. Paterniti, Jr. 2005. 1-Hydroxyalkyl-3-phenylthioureas as novel HDL-elevating agents. Bioorg. Med. Chem. Lett. 15: 809-812.
26. Sluder, A. E., and C. V. Maina. 2001. Nuclear receptors in nematodes: themes and variations. Trends Genet. 17: 206-213.
27. Ved, R., S. Saha, B. Westlund, C. Perier, L. Burnam, A. Sluder, M. Hoener, C. M. Rodrigues, A. Alfonso, C. Steer, et al. 2005. Similar patterns of mitochondrial vulnerability and rescue induced by genetic modification of alpha-synuclein, parkin, and DJ-1 in Caenorhabditis elegans. J. Biol. Chem. 280: 42655-42668.
28. Kokel, D., Y. Li, J. Qin, and D. Xue. 2006. The nongenotoxic carcinogens naphthalene and para-dichlorobenzene suppress apoptosis in Caenorhabditis elegans. Nat. Chem. Biol. 2: 338-345.
29. Evason, K., C. Huang, I. Yamben, D. F. Covey, and K. Kornfeld. 2005. Anticonvulsant medications extend worm life-span. Science. 307: 258-262.
30. Voisine, C., H. Varma, N. Walker, E. A. Bates, B. R. Stockwell, and A. C. Hart. 2007. Identification of potential therapeutic drugs for Huntington's disease using Caenorhabditis elegans. PLoS One. 2: e504.
31. Bakillah, A., Z. Zhou, J. Luchoomun, and M. M. Hussain. 1997. Measurement of apolipoprotein B in various cell lines: correlation between intracellular levels and rates of secretion. Lipids. 32: 1113-1118.
32. Athar, H., J. Iqbal, X. C. Jiang, and M. M. Hussain. 2004. A simple, rapid, and sensitive fluorescence assay for microsomal triglyceride transfer protein. J. Lipid Res. 45: 764-772.
33. Barter, P. J., C. M. Ballantyne, R. Carmena, M. Castro Cabezas, M. J. Chapman, P. Couture, J. de Graaf, P. N. Durrington, O. Faergeman, J. Frohlich, et al. 2006. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J. Intern. Med. 259: 247-258.
34. Levy, E., M. Mehran, and E. Seidman. 1995. Caco-2 cells as a model for intestinal lipoprotein synthesis and secretion. FASEB J. 9: 626-635.
35. Largis, E. E., C. H. Wang, V. G. DeVries, and S. A. Schaffer. 1989. CL 277,082: a novel inhibitor of ACAT-catalyzed cholesterol esterification and cholesterol absorption. J. Lipid Res. 30: 681-690.
36. Kubo, M., and C. A. Strott. 1987. Differential activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase in zones of the adrenal cortex. Endocrinology. 120: 214-221.
37. Levine, S., and A. Saltzman. 2007. A procedure for inducing sustained hyperlipemia in rats by administration of a surfactant. J. Pharmacol. Toxicol. Methods. 55: 224-226.
38. Ugawa, T., H. Kakuta, H. Moritani, O. Inagaki, and H. Shikama. 2003. YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents. Br. J. Pharmacol. 139: 140-146.
39. Magnin, D. R., S. A. Biller, J. Wetterau, J. A. Robl, J. K. Dickson, Jr., P. Taunk, T. W. Harrity, R. M. Lawrence, C. Q. Sun, T. Wang, et al. 2003. Microsomal triglyceride transfer protein inhibitors: discovery and synthesis of alkyl phosphonates as potent MTP inhibitors and cholesterol lowering agents. Bioorg. Med. Chem. Lett. 13: 1337-1340.
40. Robl, J. A., R. Sulsky, C. Q. Sun, L. M. Simpkins, T. Wang, J. K. Dickson, Jr., Y. Chen, D. R. Magnin, P. Taunk, W. A. Slusarchyk, et al. 2001. A novel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J. Med. Chem. 44: 851-856.
41. Schlegel, A., and D. Y. Stainier. 2006. Microsomal triglyceride transfer protein is required for yolk lipid utilization and absorption of dietary lipids in zebrafish larvae. Biochemistry. 45: 15179-15187.
42. Shin, J. E., M. J. Han, M. C. Song, N. I. Baek, and D. H. Kim. 2004. 5-Hydroxy-7-(4′-hydroxy-3′-methoxyphenyl)-1-phenyl-3-heptanone: a pancreatic lipase inhibitor isolated from Alpinia officinarum. Biol. Pharm. Bull. 27: 138-140.
43. Liao, W., and L. Chan. 2000. Apolipoprotein B, a paradigm for proteins regulated by intracellular degradation, does not undergo intracellular degradation in CaCo2 cells. J. Biol. Chem. 275: 3950-3956.
44. Benoist, F., and T. Grand-Perret. 1996. ApoB-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools. Arterioscler. Thromb. Vasc. Biol. 16: 1229-1235.
45. Au, C. S., A. Wagner, T. Chong, W. Qiu, J. D. Sparks, and K. Adeli. 2004. Insulin regulates hepatic apolipoprotein B production independent of the mass or activity of Akt1/PKBalpha. Metabolism. 53: 228-235.
46. Kong, W., J. Wei, P. Abidi, M. Lin, S. Inaba, C. Li, Y. Wang, Z. Wang, S. Si, H. Pan, et al. 2004. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 10: 1344-1351.
47. Benjannet, S., D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M. C. Asselin, J. Hamelin, M. Varret, D. Allard, et al. 2004. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279: 48865-48875.
48. Fitzgerald, K., S. Tertyshnikova, L. Moore, L. Bjerke, B. Burley, J. Cao, P. Carroll, R. Choy, S. Doberstein, Y. Dubaquie, et al. 2006. Chemical genetics reveals an RGS/G-protein role in the action of a compound. PLoS Genet. 2: e57.
49. Lackner, M. R., R. M. Kindt, P. M. Carroll, K. Brown, M. R. Cancilla, C. Chen, H. de Silva, Y. Franke, B. Guan, T. Heuer, et al. 2005. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell. 7: 325-336.
50. Dempsey, C. M., S. M. Mackenzie, A. Gargus, G. Blanco, and J. Y. Sze. 2005. Serotonin (5HT), fluoxetine, imipramine and dopamine target distinct 5HT receptor signaling to modulate Caenorhabditis elegans egg-laying behavior. Genetics. 169: 1425-1436.
51. Weinshenker, D., A. Wei, L. Salkoff, and J. H. Thomas. 1999. Block of an ether-a-go-go-like K(+) channel by imipramine rescues egl-2 excitation defects in Caenorhabditis elegans. J. Neurosci. 9831-9840.
52. Gaud, A., J. M. Simon, T. Witzel, M. Carre-Pierrat, C. G. Wermuth, and L. Segalat. 2004. Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul. Disord. 14: 365-370.
53. Ameen, C., U. Edvardsson, A. Ljungberg, L. Asp, P. Akerblad, A. Tuneld, S. O. Olofsson, D. Linden, and J. Oscarsson. 2005. Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. J. Biol. Chem. 280: 1224-1229.
54. Field, F. J., E. Born, S. Murthy, and S. N. Mathur. 2002. Poly-unsaturated fatty acids decrease the expression of sterol regulatory element-binding protein-1 in CaCo-2 cells: effect on fatty acid synthesis and triacylglycerol transport. Biochem. J. 368: 855-864.
55. Fruchart, J. C., and P. Duriez. 2006. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc). 42: 39-64.
56. Furukawa, S., and T. Hirano. 1993. Rapid stimulation of apolipoprotein B secretion by oleate is not associated with cholesteryl ester biosynthesis in HepG2 cells. Biochim. Biophys. Acta. 1170: 32-37.
57. Wilcox, L. J., P. H. Barrett, and M. W. Huff. 1999. Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J. Lipid Res. 40: 1078-1089.
58. Zhu, D., S. H. Ganji, V. S. Kamanna, and M. L. Kashyap. 2002. Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells. Atherosclerosis. 164: 221-228.
59. Silvestri, E., P. de Lange, M. Moreno, A. Lombardi, M. Ragni, A. Feola, L. Schiavo, F. Goglia, and A. Lanni. 2006. Fenofibrate activates the biochemical pathways and the de novo expression of genes related to lipid handling and uncoupling protein-3 functions in liver of normal rats. Biochim. Biophys. Acta. 1757: 486-495.
60. Turunen, M., J. Olsson, and G. Dallner. 2004. Metabolism and function of coenzyme Q. Biochim. Biophys. Acta. 1660: 171-199.